An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

Summary

This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.

Timeline

Start

2023-11-14

Primary completion

2025-10-20

Completion

2025-10-20

Drugs

Indications